Mali Okada, MD, explains the new consensus-based definitions of nonadherence and nonpersistence to anti-VEGF therapies in nAMD, recently published in Jama Ophthalmology.

The nAMD Barometer Leadership Coalition, a group of 14 retina specialists, recently published in Jama Ophthalmology a new consensus-based classification system for nonadherence and nonpersistence to anti-VEGF therapies in nAMD, using a modified Delphi method. 

In this video, Mali Okada, MD, vitreoretinal surgeon at The Royal Victorian Eye and Ear Hospital in Melbourne, Australia, speaks about the objectives and methods of this project, that should provide the framework for a more consistent assessment of patients’ engagement and outcomes of therapies, as well as the basis for meaningful interventions “tailored according to the patient, physician, and health system.” 

For further information, you can read the study here.

Okada M, et al. Defining Nonadherence and Nonpersistence to Anti-Vascular Endothelial Growth Factor Therapies in Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. 2021 Jul 1;139(7):769-776. doi: 10.1001/jamaophthalmol.2021.1660. PMID: 34081099; PMCID: PMC8176386.